Atrovent HFA Approval Breathes New Life Into Boehringer Ingelheim's Brand
This article was originally published in The Pink Sheet Daily
Executive Summary
The CFC-free version of the bronchodilator will receive three years of labeling exclusivity. FDA action to move ozone-depleting products off the market could remove BI's generic Atrovent competition.
You may also be interested in...
Spiriva Promotion Should Mention Atrovent HFA Availability, DDMAC Says
FDA’s ad division calls a Boehringer Ingelheim promotion highlighting the discontinuation of Atrovent MDI misleading.
Spiriva Promotion Should Mention Atrovent HFA Availability, DDMAC Says
FDA’s ad division calls a Boehringer Ingelheim promotion highlighting the discontinuation of Atrovent MDI misleading.
Ivax CFC-Free Albuterol Will Launch In Fourth Quarter
FDA cleared the NDA for the asthma treatment Oct. 29. Ivax’ CFC-free albuterol inhaler offers an alternative to GlaxoSmithKline’s Ventolin HFA in advance of an FDA final rule that is expected to remove CFC-propelled albuterol from the market in 2006.